In chronic obstructive pulmonary disease

Sin DD, Man SEP (2006) Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3 624-629... [Pg.366]

Cell BR, Cote CG, Marin JM et al (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New Engl J Med 350 1005-1012... [Pg.366]

Jubran A, Gross N, Ramsdell J, et al. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study. Chest 1993 103 678-84. [Pg.588]

Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004 364 709-721. [Pg.243]

A.W. Boots, G. Haenen, and A. Bast, Oxidant metabolism in chronic obstructive pulmonary disease. Eur. Respir. J. 22, 14S-27S (2003). [Pg.458]

DIAGNOSIS OF ACUTE RESPIRATORY FAILURE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE ... [Pg.936]

Ipratropium bromide is an antimuscarinic agent indicated in asthma and in chronic obstructive pulmonary disease but it is more effective in the latter. The drug is available only for inhalation because of the potential side-effects if given orally. [Pg.299]

COPD is a progressive obstruction of the airways as a consequence of small airway disease and emphysema.It is the fourth leading cause of death in developed countries. Chronic inflammation and regulated air supply in the airway are amplified in case of COPD. Decreased activity of histone deacetylase is observed in chronic obstructive pulmonary disease. ... [Pg.292]

Ito K, Ito M, Elliott MW, Cosio B, Carmaori G, Kon OM, Barczyk A, Hayashi S, Adcock LM, Hogg JC, Barnes PJ. (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. New Engl J Med 352 1957-1976. [Pg.308]

Reynolds NA, Perry CM, Keating GM. Budeso-nide/formoterol in chronic obstructive pulmonary disease. Drugs 2004 64 431-41. [Pg.85]

Skillud, D. M., Offord, K. P., and Miller, R. D. (1987). Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective matched controlled study. Ann. Int. Med. 105, 503-507. [Pg.216]

Decramer M, Rutten-van MoUcen M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC cost-utility smdy, BRONCUS) a randomised placebo-controUed trial. Lancet 2005 365(9470) 1552-60. Erratum Lancet 2005 366(9490) 984. Comment Lancet 2005 365(9470) 1518-20. [Pg.655]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...